{"id":"W1933865299","doi":"10.1158/1538-7445.sabcs14-s6-03","title":"Abstract S6-03: Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"York University","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Metastatic breast cancer; Cancer; Breast cancer; Oncology; Estrogen receptor; Bortezomib; Clinical endpoint; Progression-free survival; Randomized controlled trial; Chemotherapy; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003894092,0.0004849357,0.002152319,0.001059995,0.0001097163,0.00005170021,0.0003115796,0.0001659784,0.0004862427],"category_scores_gemma":[0.0007857559,0.000355501,0.0001591933,0.002416941,0.0007089874,0.000443344,0.00009657615,0.0009476225,0.000009501242],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002705903,"about_ca_system_score_gemma":0.008336491,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0494237,"about_ca_topic_score_gemma":0.01279849,"domain_scores_codex":[0.9936123,0.0008460599,0.00159849,0.0008880807,0.002020858,0.001034171],"domain_scores_gemma":[0.9963092,0.0007930686,0.0005120828,0.0005897427,0.0009532419,0.0008427249],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9369439,0.003023929,0.00003706267,0.0001691916,0.0004610344,0.0002123236,0.003520864,0.000261794,0.03685111,0.00003966261,0.004089758,0.01438933],"study_design_scores_gemma":[0.9690336,0.00926738,0.0005276885,0.002745931,0.0002037505,0.00001925436,0.001736644,0.0000382947,0.0145599,0.0001460813,0.001307533,0.0004139666],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9714034,0.00672275,0.00005924434,0.008880883,0.0004351761,0.01112168,0.001263139,0.00004433324,0.00006943496],"genre_scores_gemma":[0.9906082,0.0009226897,0.000638121,0.0001903498,0.0008158382,0.006028437,0.0001386714,0.0001081564,0.0005495473],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03662521,"threshold_uncertainty_score":0.9998897,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09604018843932562,"score_gpt":0.4197523491040481,"score_spread":0.3237121606647225,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}